These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 11493453)

  • 1. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression.
    Sotomayor EM; Borrello I; Rattis FM; Cuenca AG; Abrams J; Staveley-O'Carroll K; Levitsky HI
    Blood; 2001 Aug; 98(4):1070-7. PubMed ID: 11493453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.
    Cuenca A; Cheng F; Wang H; Brayer J; Horna P; Gu L; Bien H; Borrello IM; Levitsky HI; Sotomayor EM
    Cancer Res; 2003 Dec; 63(24):9007-15. PubMed ID: 14695219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity.
    Horna P; Cuenca A; Cheng F; Brayer J; Wang HW; Borrello I; Levitsky H; Sotomayor EM
    Blood; 2006 Apr; 107(7):2871-8. PubMed ID: 16339406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4
    Haabeth OAW; Fauskanger M; Manzke M; Lundin KU; Corthay A; Bogen B; Tveita AA
    Cancer Res; 2018 Aug; 78(16):4573-4585. PubMed ID: 29752262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD152 ligation by CD80 on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation.
    Chai JG; Vendetti S; Amofah E; Dyson J; Lechler R
    J Immunol; 2000 Sep; 165(6):3037-42. PubMed ID: 10975813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell contact with Ia antigens on nonhemopoietic cells in vivo can lead to immunity rather than tolerance.
    Gao EK; Kosaka H; Surh CD; Sprent J
    J Exp Med; 1991 Aug; 174(2):435-46. PubMed ID: 1677393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance.
    Wang H; Cheng F; Cuenca A; Horna P; Zheng Z; Bhalla K; Sotomayor EM
    Blood; 2005 Feb; 105(3):1135-43. PubMed ID: 15454486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors.
    Plautz GE; Mukai S; Cohen PA; Shu S
    J Immunol; 2000 Oct; 165(7):3656-62. PubMed ID: 11034369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of alloreactive CD4 T cell tolerance in molecular chimeras: a possible role for regulatory T cells.
    Forman D; Kang ES; Tian C; Paez-Cortez J; Iacomini J
    J Immunol; 2006 Mar; 176(6):3410-6. PubMed ID: 16517709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bone marrow-derived APC in the gut-associated lymphoid tissue captures oral antigens and presents them to both CD4+ and CD8+ T cells.
    Blanas E; Davey GM; Carbone FR; Heath WR
    J Immunol; 2000 Mar; 164(6):2890-6. PubMed ID: 10706674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP; Gibbs KD; Ostrand-Rosenberg S
    J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells.
    Schüler T; Blankenstein T
    J Immunol; 2003 May; 170(9):4427-31. PubMed ID: 12707316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alloreactive CD4 T cell activation in vivo: an autonomous function of the indirect pathway of alloantigen presentation.
    Reed AJ; Noorchashm H; Rostami SY; Zarrabi Y; Perate AR; Jeganathan AN; Caton AJ; Naji A
    J Immunol; 2003 Dec; 171(12):6502-9. PubMed ID: 14662850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells.
    Adler AJ; Marsh DW; Yochum GS; Guzzo JL; Nigam A; Nelson WG; Pardoll DM
    J Exp Med; 1998 May; 187(10):1555-64. PubMed ID: 9584134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
    Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
    J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo.
    Bai L; Beckhove P; Feuerer M; Umansky V; Choi C; Solomayer FS; Diel IJ; Schirrmacher V
    Int J Cancer; 2003 Jan; 103(1):73-83. PubMed ID: 12455056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.
    Lazzaro S; Giovani C; Mangiavacchi S; Magini D; Maione D; Baudner B; Geall AJ; De Gregorio E; D'Oro U; Buonsanti C
    Immunology; 2015 Oct; 146(2):312-26. PubMed ID: 26173587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct and indirect antigen presentation lead to deletion of donor-specific T cells after in utero hematopoietic cell transplantation in mice.
    Nijagal A; Derderian C; Le T; Jarvis E; Nguyen L; Tang Q; Mackenzie TC
    Blood; 2013 May; 121(22):4595-602. PubMed ID: 23610372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4-positive T cell-mediated neuroprotection requires dual compartment antigen presentation.
    Byram SC; Carson MJ; DeBoy CA; Serpe CJ; Sanders VM; Jones KJ
    J Neurosci; 2004 May; 24(18):4333-9. PubMed ID: 15128847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes.
    Robson NC; Beacock-Sharp H; Donachie AM; Mowat AM
    Immunology; 2003 Sep; 110(1):95-104. PubMed ID: 12941146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.